/ASND
ASND Stock - Ascendis Pharma A/S
Healthcare|BiotechnologyNASDAQ
$199.99+0.10%
+$0.19 (+0.10%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.59
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+27.5%upside
Target: $254.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ASND
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$197.99 – $201.99
TARGET (TP)$255.00
STOP LOSS$183.99
RISK/REWARD1:3.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.44
52W High$229.94
52W Low$118.03
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $363.64M | $266.72M | $51.17M | $7.78M | $6.95M |
| Gross Profit | $319.38M | $222.32M | $39.04M | $4.25M | $6.95M |
| Gross Margin | 87.8% | 83.4% | 76.3% | 54.7% | 100.0% |
| Operating Income | $-278,763,000 | $-455,541,000 | $-561,814,000 | $-451,792,000 | $-330,620,000 |
| Net Income | $-378,084,000 | $-481,447,000 | $-583,194,000 | $-383,577,000 | $-418,955,000 |
| Net Margin | -104.0% | -180.5% | -1139.6% | -4931.6% | -6025.5% |
| EPS | $-6.53 | $-8.55 | $-10.40 | $-7.00 | $-8.28 |
Company Overview
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Visit WebsiteRating Distribution
Strong Buy
1
8%
Buy / Outperform
8
67%
Hold / Neutral
3
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
9 Bullish3 Neutral/Bearish
Price Targets
$191
Average Target
↓ 4.7% Downside
Now
$89
Low
$191
Average
$271
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 18th 2025 | Wolfe Research | Initiation | Peer Perform | $255 |
| October 17th 2025 | Raymond James | Initiation | Strong Buy | $271 |
| July 3rd 2025 | Morgan Stanley | Resumed | Overweight | $250 |
| May 5th 2025 | Morgan Stanley | Upgrade | Overweight | $250 |
| April 16th 2025 | RBC Capital Mkts | Initiation | Outperform | $205 |
| January 7th 2025 | UBS | Initiation | Buy | $196 |
| September 5th 2024 | Oppenheimer | Upgrade | Outperform | $180 |
| June 25th 2024 | TD Cowen | Upgrade | Buy | $175← $156 |
| May 31st 2024 | Stifel | Initiation | Buy | $200 |
| December 20th 2023 | Jefferies | Initiation | Buy | $150 |
| June 14th 2023 | Credit Suisse | Resumed | Neutral | $89 |
| April 5th 2023 | Oppenheimer | Downgrade | Perform | - |
| April 4th 2023 | Morgan Stanley | Downgrade | Equal Weight | $108← $151 |
| April 3rd 2023 | Credit Suisse | Downgrade | Neutral | - |
| October 20th 2022 | Goldman | Initiation | Buy | $174 |
Earnings History & Surprises
ASNDBeat Rate
50%
Last 18 quarters
Avg Surprise
-6.6%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$-1.17
Q4 2025
EPS Surprise History
Q1 24
+24.1%
$-1.66vs$-2.19
Q2 24
-53.3%
$-2.48vs$-1.62
Q3 24
-33.1%
$-2.05vs$-1.54
Q4 24
+1.1%
$-1.81vs$-1.83
Q1 25
+43.3%
$-0.68vs$-1.20
Q2 25
-6.4%
$-1.66vs$-1.56
Q3 25
+34.5%
$-0.93vs$-1.42
Q4 25
-185.4%
$-1.17vs$-0.41
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | $0.14 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.41 | $-1.17 | -185.4% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-1.42 | $-0.93 | +34.5% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-1.56 | $-1.66 | -6.4% | ✗ MISS |
Q1 2025 | Feb 12, 2025 | $-1.20 | $-0.68 | +43.3% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-1.83 | $-1.81 | +1.1% | ✓ BEAT |
Q3 2024 | Sep 3, 2024 | $-1.54 | $-2.05 | -33.1% | ✗ MISS |
Q2 2024 | May 2, 2024 | $-1.62 | $-2.48 | -53.3% | ✗ MISS |
Q1 2024 | Feb 7, 2024 | $-2.19 | $-1.66 | +24.1% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-2.55 | $-3.08 | -21.0% | ✗ MISS |
Q3 2023 | Aug 16, 2023 | $-3.09 | $-1.54 | +50.2% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $-2.93 | $-2.18 | +25.6% | ✓ BEAT |
Q1 2023 | Feb 16, 2023 | $-2.74 | $-3.96 | -44.5% | ✗ MISS |
Q4 2022 | Nov 2, 2022 | $-2.52 | $-3.05 | -21.0% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-2.19 | $-1.50 | +31.5% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-2.09 | $-2.31 | -10.5% | ✗ MISS |
Q1 2022 | Mar 2, 2022 | $-2.57 | $-2.06 | +20.1% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-2.63 | $-1.69 | +35.8% | ✓ BEAT |
Q3 2021 | Aug 25, 2021 | $-2.75 | $-3.01 | -9.5% | ✗ MISS |
Latest News
Stifel Maintains Buy on Ascendis Pharma, Raises Price Target to $256
📈 PositiveBenzinga•Dec 11, 2025, 01:24 PM•Also:
CNBC Halftime Report Final Trades: Ascendis Pharma A/S, Monolithic Power Systems, Goldman Sachs Nasdaq-100 Premium Income ETF, iShares U.S. Consumer Discretionary ETF
➖ NeutralBenzinga•Dec 8, 2025, 06:01 PM•Also:
Ascendis Pharma's FDA PDUFA Date For TransCon CNP NDA Extended To February 28, 2026
➖ NeutralBenzinga•Nov 25, 2025, 11:55 PM
Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $220 Price Target
📈 PositiveBenzinga•Nov 18, 2025, 01:55 PM
Ascendis Pharma Announces Publication Of Pivotal Week 52 Results From Randomized Double-Blind, Placebo-Controlled ApproaCH Trial Of Investigational Once-Weekly TransCon CNP In Children With Achondroplasia In JAMA Pediatrics
📈 PositiveBenzinga•Nov 17, 2025, 09:03 PM
ASND stock has given up its prior loss. Ascendis Pharma shares were trading lower after the company reported mixed Q3 financial results.
➖ NeutralBenzinga•Nov 13, 2025, 03:12 PM
Ascendis Pharma shares are trading lower after the company reported mixed Q3 financial results.
📉 NegativeBenzinga•Nov 13, 2025, 01:30 PM
Ascendis Pharma shares are trading lower after the company reported mixed Q3 financial results.
📉 NegativeBenzinga•Nov 12, 2025, 09:14 PM
Ascendis Pharma Q3 EPS $(1.17) Misses $(0.41) Estimate, Sales $249.785M Beat $248.640M Estimate
📉 NegativeBenzinga•Nov 12, 2025, 09:02 PM
Ascendis Pharma Announces New Pooled Analysis Showing Sustained, Clinically Meaningful Improvements In Renal Function In Adults With Hypoparathyroidism Treated With TransCon PTH Through Year 3 Of Phase 2 PaTH Forward And Phase 3 PaTHway Trials
📈 PositiveBenzinga•Nov 7, 2025, 01:38 PM
Ascendis Pharma To Present Three-Year Data From Its Phase 2 And 3 Trials Showing Sustained Renal Function Improvement, Normalized Urine Calcium, And Continued Safety And Efficacy Of TransCon PTH In Adults With Hypoparathyroidism At The American Society For Nephrology's Kidney Week 2025
📈 PositiveBenzinga•Nov 3, 2025, 09:04 PM
Raymond James Initiates Coverage On Ascendis Pharma with Strong Buy Rating, Announces Price Target of $271
📈 PositiveBenzinga•Oct 17, 2025, 03:32 PM
Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $254
📈 PositiveBenzinga•Oct 13, 2025, 01:37 PM
JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $264
📈 PositiveBenzinga•Oct 9, 2025, 12:50 PM•Also:
Ascendis Pharma Submits Marketing Authorisation Application To The European Medicines Agency For TransCon CNP As A Treatment For Children With Achondroplasia
📈 PositiveBenzinga•Oct 8, 2025, 08:03 PM
Ascendis Pharma shares are trading higher. Morgan Stanley issued a Buy rating on the stock and maintained its price target of $250.
📈 PositiveBenzinga•Oct 6, 2025, 04:26 PM
MBX surges 160% on mid-stage data for hypoparathyroidism drug canvuparatide
📈 PositiveSeeking Alpha•Sep 22, 2025, 02:20 PM•Also: , ,
Ascendis To Present Latest Achondroplasia And Hypoparathyroidism Data At ASBMR 2025
➖ NeutralBenzinga•Sep 2, 2025, 08:02 PM
B of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $230
📈 PositiveBenzinga•Sep 2, 2025, 03:41 PM
JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $260
📈 PositiveBenzinga•Aug 19, 2025, 02:17 PM•Also:
Frequently Asked Questions about ASND
What is ASND's current stock price?
Ascendis Pharma A/S (ASND) is currently trading at $199.99 per share. The stock has moved +0.10% today.
What is the analyst price target for ASND?
The average analyst price target for ASND is $255.00, based on 1 analyst.
What sector is Ascendis Pharma A/S in?
Ascendis Pharma A/S operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ASND's market cap?
Ascendis Pharma A/S has a market capitalization of $12.05 billion, making it a large-cap company.
Does ASND pay dividends?
No, Ascendis Pharma A/S does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBBIO
BridgeBio Pharma, Inc.
$76.30
Mkt Cap: $14.5B
BMRN
BioMarin Pharmaceutical Inc.
$61.15
Mkt Cap: $11.7B
EXEL
Exelixis, Inc.
$44.30
Mkt Cap: $11.9B
GH
Guardant Health, Inc.
$99.74
Mkt Cap: $12.4B
IONS
Ionis Pharmaceuticals, Inc.
$79.57
Mkt Cap: $12.6B
MDGL
Madrigal Pharmaceuticals, Inc.
$591.02
Mkt Cap: $13.1B
MRNA
Moderna, Inc.
$33.80
Mkt Cap: $13.2B
ROIV
Roivant Sciences Ltd.
$22.41
Mkt Cap: $15.6B
RVMD
Revolution Medicines, Inc.
$78.78
Mkt Cap: $15.2B
SMMT
Summit Therapeutics Inc.
$17.82
Mkt Cap: $13.3B
Explore stocks similar to ASND for comparison